We provide you with 20 years of free, institutional-grade data for CYTH stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CYTH. Explore the full financial landscape of CYTH stock.
| Reported Date | CIK | Ticker | Type |
|---|
Cyclo Therapeutics, Inc(NASDAQ:CYTH) 
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related ...
Website: https://www.cyclotherapeutics.com/
Founded: 1990
CEO: Scott Fine
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Share this website to your friends
The information provided in this report about CYTH stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.